SalesTrax.com Research: Novartis Pharmaceutical

Articles found below have been submitted through various PR and news sources and don’t necessary reflect the views of SalesTrax or its employees.


Pharmaceutical Business Review

2009-09-18 04:04
FDA Approves Novartis' Valturna
Valturna, a single-pill combination of valsartan and aliskiren, to treat high blood pressure

2009-09-15 12:05
Novartis Provides Results From Phase III Trial Of QAB149
QAB149 has shown to significantly improve lung function and provide reduction in breathlessness compared to tiotropium

2009-09-02 12:04
Novartis' Diovan Reduces Cardiovascular Events By 45%
Trial conducted on 3,042 Japanese patients with high blood pressure uncontrolled on a previous non-ARB-based regimen

2009-09-01 04:04
Nuevolution Enters Into Research Collaboration With Novartis
Collaboration to use Chemetics drug discovery technology, to identify small molecule leads against drug targets of Novartis' interest

2009-08-31 04:03
Orexo Signs Worldwide Licensing Agreement With Novartis
Novartis to fund all future development of the product

2009-08-29 04:03
Novartis India Introduces Otrivin In Nasal Spray Format
Otrivin, indicated for the symptomatic relief of nasal congestion

2009-08-24 12:03
EC Approves Novartis' Xolair
To treat children aged 6 to 11 years suffering from severe persistent allergic asthma

2009-08-24 12:03
UCB Signs Licensing Agreement With Novartis
To commercialise cardiovascular and diabetes products in Germany

2009-08-20 12:03
Novartis' Femara Shows To Be Superior To Tamoxifen
Femara, an optimal treatment vs tamoxifen in postmenopausal women in breast cancer

2009-08-17 12:03
Novartis Receives FDA Approval For Extavia
Extavia, for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations

2009-08-10 04:02
Opexa Signs Development Agreement With Novartis
Agreement to help Opexa focus its attention on Tovaxin

2009-07-30 12:03
FORMA Signs Collaboration Deal With Novartis
To discover inhibitors for undisclosed protein-protein interaction targets in oncology

2009-07-28 08:03
Avila Signs Agreement With Novartis To Develop Novel Covalent Drug Candidate
Novel Covalent Drug, to treat many serious diseases through a novel mechanism called protein silencing

2009-07-22 08:02
FDA Approves Novartis' Tekturna HCT Tablets
Tekturna HCT tablets is intended for patients who need multiple drugs for blood pressure

2009-07-20 04:04
Novartis Extends Alnylam?s RNAi Therapeutics Collaboration
Collaboration is focused on the discovery, development and commercialization of RNAi therapeutics

2009-07-16 12:04
Novartis' First Half Net Income Declines 12%
Company' net income in the second quarter of 2009 went down by 10%

2009-07-09 04:03
Japanese Ministry Of Health Approves Novartis? Rasilez
For the treatment of high blood pressure alone or in combination with other high blood pressure medicines

2009-07-07 04:03
MorphoSys Secures Full-term Strategic Alliance With Novartis
Collaboration to run until 2017, and may be extended by Novartis for an additional two years

2009-07-06 12:03
Novartis Delivers 250 millionth Of Coartem Treatment
Company is said to be the first healthcare company to join United Against Malaria (UAM)

2009-07-02 04:04
Novartis Receives Complete Response Letter From FDA For Menveo
FDA has requested additional information on clinical and CMC sections of BLA

2009-06-29 12:04
Novartis Initiates Phase-III Clinical Study Of NVA237
Patient to be randomised to receive once-daily dose of placebo, tiotropium bromide or 50g of NVA237 for a 52-week period

2009-06-26 04:04
Novartis Reports Positive Result For Phase-II Trial Of Afinitor, Sandostatin LAR
Showed patients, who received Afinitor in combination with Sandostatin LAR, remained progression-free for 16.7 months

2009-06-18 12:03
Novartis Receives FDA Approval For Ilaris
Ilaris, a fully human monoclonal antibody that rapidly and selectively blocks IL-1

2009-06-15 04:04
Novartis Produces First Batch Of Swine Flu Vaccine
Vaccine produced at Novartis plant in Marburg, Germany

2009-06-12 12:04
Regeneron Signs Two Royalty Agreements With Novartis
Regeneron to receive royalties on worldwide sales of canakinumab

2009-06-08 12:03
Novartis' Afinitor Shows Positive Result for Patients With Lymphoma
Reduced tumor size by 50% in one out of three patients with refractory or relapsed lymphoma.

2009-06-08 04:03
Novartis' Tasigna Positive In Treating Chronic Myeloid Leukemia
Research compared Tasigna against Glivec (imatinib) data

2009-06-04 12:03
Novartis' Ilaris Offers Long Term Remission For CAPS
90% of cryopyrin-associated periodic syndrome (CAPS) patients treated with Ilaris (canakinumab, formerly ACZ885) remained in remission

2009-06-04 12:03
Novartis, Wellcome Trust To Develop Vaccine For Typhoid Fever
E5.15 million granted to fund preclinical development and phase I and II clinicla trial studies for the vaccine

2009-06-02 12:03
Novartis Pharma, Nordic Bioscience' Phase III Study For Knee Osteoarthritis Treatment
Novartis Pharmaceuticals and Nordic Bioscience have completed the enrollment for the Phase III study on oral formulation of salmon calcitonin. The study explores the safety and efficacy of this oral formulation using Emisphere?s Eligen technology to treat patients with osteoarthritis of the knee.

2009-06-01 04:03
CHMP Recommends Novartis' EU Approved Afinitor For Patients With Advanced Kidney Cancer
Novartis has received a positive response from the Committee for Medicinal Products for Human Use (CHMP), supporting European Union (EU) approval of Afinitor (everolimus) tablets for the treatment of patients with advanced renal cell carcinoma (RCC).


Forbes.com

2010-01-27 20:00
Big Pharma's Best Chief Steps Down
Novartis' Dan Vasella has done better than his peers. Now he is handing over the reins.

2009-12-08 12:00
Novartis' Cancer Plan
The Swiss drug company hopes that new cancer drugs will reduce its reliance on Gleevec.